Powered Drug Discovery Laboratory with Eli Lilly
Nvidia Corp. announced a $1 billion, five-year investment in a Silicon Valley laboratory partnership with Eli Lilly & Co. to accelerate AI adoption in pharmaceutical research. The facility aims to automate traditionally human-dependent drug discovery processes, combining Lilly's lab expertise with Nvidia's AI innovation capabilities. This partnership builds on an earlier collaboration to create a powerful pharmaceutical industry supercomputer at Lilly's Indianapolis headquarters, operational in the first quarter. The investment represents Nvidia's strategic expansion into healthcare markets, diversifying beyond its current dependence on major technology customers for AI accelerator chip revenue.
